HRP20201722T1 - Minitablete melatonina i postupak njihove proizvodnje - Google Patents
Minitablete melatonina i postupak njihove proizvodnje Download PDFInfo
- Publication number
- HRP20201722T1 HRP20201722T1 HRP20201722TT HRP20201722T HRP20201722T1 HR P20201722 T1 HRP20201722 T1 HR P20201722T1 HR P20201722T T HRP20201722T T HR P20201722TT HR P20201722 T HRP20201722 T HR P20201722T HR P20201722 T1 HRP20201722 T1 HR P20201722T1
- Authority
- HR
- Croatia
- Prior art keywords
- melatonin
- minitablet
- patient
- release
- controlled
- Prior art date
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims 28
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims 28
- 229960003987 melatonin Drugs 0.000 title claims 28
- 239000008185 minitablet Substances 0.000 title claims 28
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 238000013270 controlled release Methods 0.000 claims 16
- 238000000034 method Methods 0.000 claims 14
- 229920001577 copolymer Polymers 0.000 claims 9
- 239000003937 drug carrier Substances 0.000 claims 8
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 6
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims 6
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 6
- 229960001021 lactose monohydrate Drugs 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 230000036765 blood level Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 230000033764 rhythmic process Effects 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 238000007580 dry-mixing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Minitableta melatonina s kontroliranim otpuštanjem, naznačena time što sadrži:
terapijski djelotvornu količinu melatonina; i
jedan ili više farmaceutski prihvatljivih nosača;
gdje minitableta ima promjer manji od ili jednak 4 mm; i
gdje farmaceutski prihvatljivi nosači sadrže jedan ili više od kalcijevog hidrogenfosfata dihidrata, amonio metakrilatnog kopolimera i laktoze monohidrata, i
gdje je težinski omjer između melatonina, amonio metakrilatnog kopolimera, kalcijevog hidrogenfosfata dihidrata i laktoze monohidrata 1:1,1-5,9:0,8-8,3:1,8-8,8.
2. Minitableta melatonina s kontroliranim otpuštanjem u skladu s patentnim zahtjevom 1, naznačena time što ima profil otpuštanja gdje se manje od 50 % melatonina otpušta unutar 1 sata, a otprilike više od 70 % melatonina se otpušta unutar 6 sati.
3. Minitableta melatonina s kontroliranim otpuštanjem u skladu s patentnim zahtjevima 1 ili 2, naznačena time što se minitabletu tako formulira da dovodi do minimalne razine u krvi od otprilike 60 do otprilike 200 pikograma, po mogućnosti otprilike 100 do otprilike 200 pikograma melatonina na mililitru u trajanju od najmanje četiri sata nakon oralnog unosa minitablete melatonina s kontroliranim otpuštanjem od strane ljudskog pacijenta.
4. Minitableta melatonina s kontroliranim otpuštanjem u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što se minitabletu oblaže farmaceutski prihvatljivom oblogom.
5. Postupak proizvodnje minitablete melatonina s kontroliranim otpuštanjem, naznačen time što se postupak sastoji u: kombiniranju terapijski djelotvorne količine melatonina s jednim ili više farmaceutski prihvatljivih nosača kako bi se dobilo smjesu; i komprimiranju smjese u minitablete od kojih svaka ima promjer manji od ili jednak 4 mm,
gdje farmaceutski prihvatljivi nosači sadrže jedan ili više od kalcijevog hidrogenfosfata dihidrata, amonio metakrilatnog kopolimera i laktoze monohidrata, i
gdje je težinski omjer između melatonina, amonio metakrilatnog kopolimera, kalcijevog hidrogenfosfata dihidrata i laktoze monohidrata 1:1,1-5,9:0,8-8,3:1,8-8,8.
6. Postupak u skladu s patentnim zahtjevom 5, naznačen time što dodatno uključuje korak oblaganja tableta farmaceutski prihvatljivom oblogom.
7. Postupak u skladu s patentnim zahtjevima 5 ili 6, naznačen time što je komprimiranje takvo da minitableta ima profil kontroliranog otpuštanja gdje se manje od 50 % melatonina otpušta unutar 1 sata otapanja, a otprilike više od 70 % melatonina se otpušta unutar 6 sati otapanja.
8. Postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 7, naznačen time što se korak kombiniranja sastoji u suhom miješanju terapijski djelotvorne količine melatonina s jednim ili više farmaceutski prihvatljivih nosača.
9. Minitableta melatonina s kontroliranim otpuštanjem u skladu s bilo kojim od patentnih zahtjeva 1 do 4 ili postupak u skladu s bilo kojim od patentnih zahtjeva 5 do 8, naznačeni time što minitableta ili jedan ili više farmaceutski prihvatljivih nosača sadrže brzo otapajući šećer ili alkohol koji nije laktoza.
10. Minitableta s kontroliranim otpuštanjem u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time što je namijenjena upotrebi
a) u postupku induciranja spavanja kod pacijenta kojem je to potrebno, gdje se postupak sastoji u oralnoj primjeni minitablete s kontroliranim otpuštanjem na pacijentu, gdje se spavanje inducira kod pacijenta,
b) u postupku oralne primjene melatonina na pacijentu koji ima poteškoća s gutanjem tableta ili kapsula, gdje se postupak sastoji u oralnoj primjeni minitablete s kontroliranim otpuštanjem na pacijentu, ili
c) u postupku induciranja pomaka faze dnevnog ritma pacijenta kojem je to potrebno, gdje se postupak sastoji u oralnoj primjeni minitablete s kontroliranim otpuštanjem na pacijentu, gdje se inducira pomak faze dnevnog ritma pacijenta.
11. Minitableta s kontroliranim otpuštanjem namijenjena upotrebi u skladu s patentnim zahtjevom 10 a), naznačena time što je pacijent pedijatrijski pacijent ili gerijatrijski pacijent, i/ili što se minitabletu primjenjuje prije spavanja ili između prvog perioda spavanja i drugog perioda spavanja.
12. Minitableta melatonina s kontroliranim otpuštanjem u skladu s bilo kojim od patentnih zahtjeva 1-4 ili minitableta s kontroliranim otpuštanjem namijenjena upotrebi u skladu s patentnim zahtjevima 10 ili 11, naznačena time što je terapijski djelotvorna količina melatonina 1 mg, 2 mg, 3 mg, 4 mg ili 5 mg.
13. Minitableta melatonina s kontroliranim otpuštanjem u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time što je amonio metakrilatni kopolimer amonio metakrilatni kopolimer tipa A ili amonio metakrilatni kopolimer tipa B.
14. Farmaceutski proizvod koji sadrži jednu ili više minitableta melatonina koje mogu inducirati spavanje kod pacijenta i postizanje minimalne razine u krvi od otprilike 60 do otprilike 200 pikograma melatonina na mililitru u trajanju od najmanje četiri sata nakon primjene bez izazivanja neprihvatljivih nuspojava kod čovjeka, namijenjen upotrebi u postupku sigurnog induciranja i održavanja sna kod pacijenta kojem je to potrebno, naznačen time što se postupak sastoji u:
(a) osiguravanju farmaceutskog proizvoda i
(b) oralnoj primjeni jedne ili više minitableta na pacijentu,
gdje se navedeni farmaceutski proizvod proizvodi kombiniranjem terapijski djelotvorne količine melatonina s jednim ili više farmaceutski prihvatljivih nosača kako bi se dobilo smjesu, komprimiranjem smjese u jednu ili više minitableta od kojih svaka ima promjer manji od ili jednak 4 mm, tako da minitableta ima profil otpuštanja gdje se manje od 50 % melatonina otpušta unutar 1 sata, a otprilike više od 70 % melatonina se otpušta unutar 6 sati, uz moguće punjenje više minitableta u kapsulu,
gdje farmaceutski prihvatljivi nosači sadrže jedan ili više od kalcijevog hidrogenfosfata dihidrata, amonio metakrilatnog kopolimera i laktoze monohidrata, i
gdje je težinski omjer između melatonina, amonio metakrilatnog kopolimera, kalcijevog hidrogenfosfata dihidrata i laktoze monohidrata 1:1,1-5,9:0,8-8,3:1,8-8,8.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415014P | 2016-10-31 | 2016-10-31 | |
| EP16805903.8A EP3337462B1 (en) | 2016-10-31 | 2016-11-29 | Melatonin mini-tablets and method of manufacturing the same |
| PCT/IB2016/057190 WO2018078429A1 (en) | 2016-10-31 | 2016-11-29 | Melatonin mini-tablets and method of manufacturing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201722T1 true HRP20201722T1 (hr) | 2021-03-05 |
Family
ID=57482481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201722TT HRP20201722T1 (hr) | 2016-10-31 | 2020-10-26 | Minitablete melatonina i postupak njihove proizvodnje |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10722494B2 (hr) |
| EP (2) | EP3777842A1 (hr) |
| JP (1) | JP6830156B2 (hr) |
| KR (1) | KR102167190B1 (hr) |
| CN (1) | CN109922795B (hr) |
| AU (5) | AU2016426598C1 (hr) |
| CA (1) | CA3040027C (hr) |
| CY (1) | CY1123449T1 (hr) |
| DK (1) | DK3337462T3 (hr) |
| ES (1) | ES2828034T3 (hr) |
| HR (1) | HRP20201722T1 (hr) |
| HU (1) | HUE051362T2 (hr) |
| IL (1) | IL262537B (hr) |
| LT (1) | LT3337462T (hr) |
| MX (1) | MX2019004736A (hr) |
| NZ (1) | NZ747702A (hr) |
| PL (1) | PL3337462T3 (hr) |
| PT (1) | PT3337462T (hr) |
| RS (1) | RS61024B1 (hr) |
| SG (1) | SG11201903829PA (hr) |
| SI (1) | SI3337462T1 (hr) |
| TW (1) | TWI787164B (hr) |
| WO (1) | WO2018078429A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230017814A (ko) * | 2020-10-26 | 2023-02-06 | 일동제약(주) | 옥수수불검화추출물을 포함하는 소형화된 경구투여 제제의 제조방법 및 이에 따라 제조된 소형화 제제 |
| WO2024079125A1 (en) | 2022-10-14 | 2024-04-18 | Société des Produits Nestlé S.A. | Sustained release melatonin compositions |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600723A (en) | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
| EP0518468B1 (en) | 1991-05-09 | 1999-06-30 | Neurim Pharmaceuticals (1991) Limited | Melatonin containing compositions |
| DK0565296T3 (da) | 1992-04-07 | 1996-12-09 | Neurim Pharma 1991 | Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi |
| US5449683A (en) | 1992-10-01 | 1995-09-12 | Massachussetts Institute Of Technology | Methods of inducing sleep using melatonin |
| WO1995003043A1 (en) * | 1993-07-26 | 1995-02-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Sustained release oral compositions containing melatonin |
| US6469044B1 (en) * | 1995-02-01 | 2002-10-22 | Neurim Pharmaceuticals (1991) Ltd. | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
| SK284521B6 (sk) * | 1995-02-01 | 2005-05-05 | Neurim Pharmaceuticals (1991) Ltd. | Použitie melatonínu na prípravu farmaceutického prostriedku |
| FR2762513B1 (fr) * | 1997-04-23 | 2003-08-22 | Permatec Pharma Ag | Comprimes bioadhesifs |
| WO2000018374A1 (en) * | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| DE60034373T2 (de) * | 2000-01-05 | 2007-12-20 | Neurim Pharmaceuticals (1991) Ltd. | Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen |
| US6458384B2 (en) * | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
| IL144900A (en) | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
| IL149377A (en) * | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
| KR20030016215A (ko) * | 2002-07-05 | 2003-02-26 | 뉴림 파머슈티칼스 (1991) 리미티드 | 항고혈압제에 대한 내성 및 관련 질환의 치료를 위한 방법및 제형 |
| WO2004067039A1 (en) * | 2003-01-28 | 2004-08-12 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| US20050164987A1 (en) | 2003-12-24 | 2005-07-28 | Barberich Timothy J. | Melatonin combination therapy for improving sleep quality |
| FR2889811B1 (fr) * | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| DE102006006532B4 (de) | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
| CN101754753A (zh) | 2007-05-24 | 2010-06-23 | 纽约市哥伦比亚大学托管会 | 褪黑素的持久释放配方 |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| US8691275B2 (en) | 2011-01-28 | 2014-04-08 | Zx Pharma, Llc | Controlled-release melatonin compositions and related methods |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
| ES2677247T3 (es) | 2014-05-28 | 2018-07-31 | Valpharma S.P.A. | Formulación para administración oral que comprende melatonina en forma estable y método de producción de la misma |
-
2016
- 2016-11-29 HU HUE16805903A patent/HUE051362T2/hu unknown
- 2016-11-29 PT PT168059038T patent/PT3337462T/pt unknown
- 2016-11-29 ES ES16805903T patent/ES2828034T3/es active Active
- 2016-11-29 AU AU2016426598A patent/AU2016426598C1/en active Active
- 2016-11-29 PL PL16805903T patent/PL3337462T3/pl unknown
- 2016-11-29 SG SG11201903829PA patent/SG11201903829PA/en unknown
- 2016-11-29 WO PCT/IB2016/057190 patent/WO2018078429A1/en unknown
- 2016-11-29 EP EP20195788.3A patent/EP3777842A1/en active Pending
- 2016-11-29 JP JP2019519420A patent/JP6830156B2/ja active Active
- 2016-11-29 NZ NZ747702A patent/NZ747702A/en active IP Right Revival
- 2016-11-29 CN CN201680090550.4A patent/CN109922795B/zh active Active
- 2016-11-29 CA CA3040027A patent/CA3040027C/en active Active
- 2016-11-29 LT LTEP16805903.8T patent/LT3337462T/lt unknown
- 2016-11-29 RS RS20201242A patent/RS61024B1/sr unknown
- 2016-11-29 EP EP16805903.8A patent/EP3337462B1/en active Active
- 2016-11-29 SI SI201630947T patent/SI3337462T1/sl unknown
- 2016-11-29 KR KR1020187035251A patent/KR102167190B1/ko active IP Right Grant
- 2016-11-29 MX MX2019004736A patent/MX2019004736A/es unknown
- 2016-11-29 DK DK16805903.8T patent/DK3337462T3/da active
- 2016-12-26 TW TW105143159A patent/TWI787164B/zh active
-
2018
- 2018-10-24 IL IL262537A patent/IL262537B/en active IP Right Grant
- 2018-10-31 US US16/176,338 patent/US10722494B2/en active Active
-
2019
- 2019-01-24 AU AU2019200479A patent/AU2019200479B2/en active Active
- 2019-11-28 AU AU2019101470A patent/AU2019101470B4/en active Active
-
2020
- 2020-06-16 US US16/902,419 patent/US10869857B2/en active Active
- 2020-10-14 CY CY20201100971T patent/CY1123449T1/el unknown
- 2020-10-26 HR HRP20201722TT patent/HRP20201722T1/hr unknown
-
2021
- 2021-01-18 AU AU2021200268A patent/AU2021200268A1/en not_active Abandoned
-
2023
- 2023-03-31 AU AU2023202003A patent/AU2023202003A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2202652T3 (es) | Formulaciones farmaceuticas de liberacion retardada de droga. | |
| KR101834033B1 (ko) | 주의력 결핍 장애 치료용 고체 경구 제약 조성물 | |
| ES488168A0 (es) | Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada. | |
| BR9814378A (pt) | Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase | |
| HRP20201722T1 (hr) | Minitablete melatonina i postupak njihove proizvodnje | |
| ES2749800T3 (es) | Formulación de liberación sostenida de naltrexona | |
| ITMI20101374A1 (it) | Procedimento per la preparazione di compresse a rilascio controllato comprendenti melatonina | |
| JP2019533672A5 (hr) | ||
| JP2017515858A5 (hr) | ||
| US20230285369A1 (en) | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder | |
| TWI744858B (zh) | 治療精神疾病之控釋藥物組合物和方法 | |
| US10849856B2 (en) | Melatonin mini-tablets and method of manufacturing the same | |
| RU2013124994A (ru) | КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| FI4065134T3 (fi) | Rautasuksinaatin antaminen suun kautta käytettäväksi raudanpuutoksen hoidossa potilailla, joilla on sydämen vajaatoiminta | |
| Patil | A Review: A new trend in drug delivery Oro-dispersible tablets | |
| Malpure et al. | Effect of rupturable and erodible polymers in the outer shell of press coated tablet | |
| Lalla et al. | Controlled-release isosorbide dinitrate pellets. Part II: In vivo studies | |
| JPS6360926A (ja) | 感冒薬 | |
| Hadi | Development and evaluation of mini-tablets-filed-capsule system for chronotherapeutic delivery of montelukast |